915-P: Characteristics of Teens with T1D That Predict Family T1D Management over Time

Abstract

Aim: Adolescence is challenging for T1D management. To identify families that need more support during this time, we assessed individual and family characteristics that predict adverse communication/behaviors related to T1D care. Method: Teens with T1D (N=283) and a parent (83% mothers) completed validated measures of parent involvement in care, diabetes-specific family conflict, negative affect regarding BG monitoring, and T1D self-care at 0, 6, and 12 mo. We used linear mixed models to assess how baseline characteristics (sex, age, T1D duration, A1c, BG monitoring frequency, injection vs. pump therapy, and parent education) predicted T1D behaviors over 12 months. Results: At baseline, teens (51% male, 32% non-white, 60% pump-treated) had M±SD age 15.0±1.3 years, T1D duration 6.6±3.8 years, and A1c 8.5±1.1%. Significant modifiable and non-modifiable predictors of poorer outcomes are shown (Table). Diabetes family conflict was higher in younger teens, those with higher A1c, and teens with parents without a college degree. T1D management (parent involvement, teen self-care) was poorer for older teens and those on injections. Summary: To prevent adverse family behaviors, clinicians can target modifiable factors (e.g., glycemic control, treatment modality). Clinicians can also provide support to families of teens with non-modifiable risk factors (e.g., lower parent education, younger teens with family conflict). Disclosure R. M. Wasserman: None. L. J. Tinsley: None. P. V. Commissariat: None. L. K. Volkening: None. L. M. Laffel: Consultant; Self; AstraZeneca, Boehringer Ingelheim International GmbH, Dexcom, Inc., Dompe, Insulogic LLC, Janssen Pharmaceuticals, Inc., Laxmi Therapeutic Devices, LifeScan, Lilly Diabetes, Medtronic, Provention Bio, Inc. B. Anderson: None. Funding National Institutes of Health (R01DK095273, P30DK036836); JDRF (2-SRA-2014-253-M-B)